LL-37
A host-defense peptide associated with innate immunity and tissue-response discussions.
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when LL-37 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research area, not by vendor shelf placement.
No major aliases are tracked for this profile yet.
No FDA label signal · 98 trials · 4333 PubMed results
LL-37 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
LL-37 has 15 name-matched clinical trials (highest phase: Phase 4) and 4333 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What LL-37 is
LL-37 is a human antimicrobial peptide involved in innate immune signaling. In peptide-market contexts it is usually discussed in relation to host defense, inflammation, or tissue response.
Why it matters
It adds a genuine immune-facing profile to the library and helps keep the peptide catalog from collapsing into only obesity and recovery topics.
Regulatory context
LL-37 is not an FDA-approved peptide medicine for consumer use in the United States.
Practical reading note
Immune-related compounds are especially easy to overstate, so the most useful framing is what biological lane a peptide belongs to, not whether a vendor presents it as a broad health solution.